A new US$85 million program to help women in multiple countries in sub-Saharan Africa protect themselves from HIV has been launched, MOSAIC (Maximizing Options to Advance Informed Choice for HIV Prevention), is implemented by a consortium of partners led by FHI 360 with a range of local partners. Wits RHI is part of the core strategic leadership group for all consortium activities.
Interim results of the REACH study of daily oral PrEP and monthly dapivirine vaginal ring presented at IAS 2021 – the 11th IAS Conference on HIV Science
Early unblinding of the pre-exposure prophylaxis regimen of long-acting cabotegravir (CAB LA) is a milestone for prevention of HIV among women in sub Saharan Africa
The first CROWN CORONATION participants in Africa will be enrolled at the Wits RHI Ward 21 CRS this week. Scientists from Wits RHI led by Prof Sinead Delany-Moretlwe and the University of Cape Town are launching a clinical trial to test whether the childhood vaccine for measles, mumps and rubella (MMR) can protect frontline healthcare workers from COVID-19 or reduce the severity of illness for those who do become infected.
Wits is the lead institution in South Africa for a second COVID-19 vaccine trial and will begin screening participants for the NVX-CoV2373 trial today. The Phase 2 trial in South Africa will evaluate if the nanoparticle S-protein, in the COVID-19 vaccine known as NVX-CoV2373, protects against COVID-19 disease in adults aged 18-64-years-old.
Positive opinion by European Medicines Agency paves way for IPM to pursue approvals of dapivirine ring in African countries MTN studies of ring’s safety in girls and pregnant and breastfeeding women taking place in parallel A vaginal ring intended to be used for a month at a time has moved one step closer to potentially becoming a new HIV prevention method for cisgender women in sub-Saharan Africa, who despite being the face of the epidemic, have few options for protecting themselves against getting infected.
Strict Adherence to Daily PrEP is Especially Important in Pregnancy, Investigators Conclude. Among African adolescent girls and young women who took HIV pre-exposure prophylaxis (PrEP) daily, levels of the PrEP drug tenofovir were more than 30% lower in those who were pregnant than in those who had recently given birth. All 40 study participants took PrEP under direct observation, confirming their near-perfect adherence. PrEP drug levels were lower to a similar degree in the pregnant African adolescent girls and young women compared to American men and non-pregnant, non-lactating women who took PrEP daily under direct observation in an earlier study. These findings from the NIH-funded IMPAACT 2009 study were reported today at the Conference on Retroviruses and Opportunistic Infections (CROI)
Wits RHI Shandukani Research Centre is pleased to inform the public and all relevant stakeholders that the site has successfully enrolled its first participant into MTN 042, or DELIVER, a Phase 3b safety study of the monthly dapivirine vaginal ring and Truvada as daily oral pre-exposure prophylaxis (PrEP) in pregnant women.
Mexico City, 24 July 2019 – South African study shows that dolutegravir-containing regimens perform as well as the current efavirenz-containing one used for first-line antiretroviral treatment (ART) in South Africa and most of Africa. These data are important in showing how dolutegravir and a new form of tenofovir (called tenofovir alafenamide or TAF) perform in African populations, and in providing the scientific backing for the move to dolutegravir-containing regimens from efavirenz-containing ones worldwide. The initial study results are also published today in the most prestigious medical journal in the world, The New England Journal of Medicine.
ECHO finds no substantial difference in HIV risk among DMPA-IM,copper IUD, and LNG implant users. DURBAN (South Africa) 13 June 2019 – A pivotal clinical trial to address a long-standing question about the relationship between hormonal contraceptive use and the risk of HIV acquisition has found no substantial difference in HIV risk among 7,829 African women who were randomly assigned to use one of three highly effective methods of contraception.